1. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib
   Ashley L. Cole et al, 2020, JCO Oncology Practice CrossRef
2. Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity
   Maheema Bhaskar et al, 2022, Indian Journal of Medical and Paediatric Oncology CrossRef
3. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
   Takashi Hamada et al, 2018, Clinical Drug Investigation CrossRef
4. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
   Philippe Rousselot et al, 2021, British Journal of Haematology CrossRef
5. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
   Nuno Cerveira et al, 2018, BMC Cancer CrossRef
6. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients
   Yoshimichi Koutake et al, 2020, International Journal of Hematology CrossRef
7. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
   Noriyoshi Iriyama et al, 2018, Internal Medicine CrossRef
8. A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion
   Adam Alter et al, 2018, Chest CrossRef